{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:56:25Z","timestamp":1784548585907,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020275","name":"TauRx Pharmaceuticals","doi-asserted-by":"publisher","award":["PAR1577"],"award-info":[{"award-number":["PAR1577"]}],"id":[{"id":"10.13039\/100020275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The accumulation of \u03b1-synuclein (\u03b1-Syn) into Lewy bodies is a hallmark of synucleinopathies, a group of neurological disorders that include Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB). Small oligomers as well as larger fibrils of \u03b1-Syn have been suggested to induce cell toxicity leading to a degenerative loss of neurones. A richer understanding of \u03b1-Syn aggregation in disease, however, requires the identification of the different \u03b1-Syn species and the characterisation of their biochemical properties. We here aimed at a more in-depth characterisation of the \u03b1-Syn transgenic mice, Line 62 (L62), and examined the deposition pattern and solubility of human and murine \u03b1-Syn in these mice using immunohistochemical and biochemical methods. Application of multiple antibodies confirmed mAb syn204 as the most discriminatory antibody for human \u03b1-Syn in L62. Syn204 revealed an intense and widespread immunohistochemical \u03b1-Syn labelling in parietal cortex and hippocampus, and to a lower level in basal forebrain and hindbrain regions. The labelled \u03b1-Syn represented somatic inclusions as well as processes and synaptic endings. Biochemical analysis revealed a Triton-resistant human \u03b1-Syn pool of large oligomers, a second pool of small oligomers that was not resistant to solubilization with urea\/Triton. A third SDS-soluble pool of intermediate sized aggregates containing a mixture of both, human and mouse \u03b1-Syn was also present. These data suggest that several pools of \u03b1-Syn can exist in neurones, most likely in different cellular compartments. Information about these different pools is important for the development of novel disease modifying therapies aimed at \u03b1-Syn.<\/jats:p>","DOI":"10.1038\/s41598-024-56735-6","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T21:24:39Z","timestamp":1710451479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Solubility of \u03b1-synuclein species in the L62 mouse model of synucleinopathy"],"prefix":"10.1038","volume":"14","author":[{"given":"Karima","family":"Schwab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Magbagbeolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Theuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Wischik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"56735_CR1","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","volume":"90","author":"K Ueda","year":"1993","unstructured":"Ueda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 11282\u201311286 (1993).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"56735_CR2","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1074\/jbc.M008919200","volume":"276","author":"BI Giasson","year":"2001","unstructured":"Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q. & Lee, V. M. Y. A hydrophobic stretch of 12 amino acid residues in the middle of \u03b1-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380\u20132386 (2001).","journal-title":"J. Biol. Chem."},{"key":"56735_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"H Lashuel","year":"2013","unstructured":"Lashuel, H. The many faces of \u03b1-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat Rev Neurosci."},{"key":"56735_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tcb.2017.02.002","volume":"27","author":"J Lautenschl\u00e4ger","year":"2017","unstructured":"Lautenschl\u00e4ger, J., Kaminski, C. F. & Kaminski Schierle, G. S. \u03b1-synuclein\u2014Regulator of exocytosis, endocytosis, or both?. Trends Cell Biol. 27, 468\u2013479 (2017).","journal-title":"Trends Cell Biol."},{"key":"56735_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.00028","volume":"13","author":"M Huang","year":"2019","unstructured":"Huang, M. et al. \u0391-Synuclein: A multifunctional player in exocytosis, endocytosis, and vesicle recycling. Front. Neurosci. 13, 1\u20138 (2019).","journal-title":"Front. Neurosci."},{"key":"56735_CR6","doi-asserted-by":"publisher","first-page":"11113","DOI":"10.1073\/pnas.1903049116","volume":"166","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Functional cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling. Proc. Natl. Acad. Sci. USA 166, 11113\u201311115 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"56735_CR7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9, J. et al. \u03b1-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663\u20131667 (2010).","journal-title":"Science"},{"key":"56735_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren, A. et al. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 139, 977\u20131000 (2020).","journal-title":"Acta Neuropathol."},{"key":"56735_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. \u03b1-Synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"56735_CR10","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba, M. et al. Aggregation of \u03b1-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879\u2013884 (1998).","journal-title":"Am. J. Pathol."},{"key":"56735_CR11","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"56735_CR12","first-page":"16","volume":"920","author":"M Grazia","year":"2000","unstructured":"Grazia, M. & Goedert, M. Parkinson\u2019s disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Mol. Basis Dement. 920, 16\u201327 (2000).","journal-title":"Mol. Basis Dement."},{"key":"56735_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi, J. C. & Hirth, F. Mechanisms of \u03b1-Synuclein induced synaptopathy in parkinson\u2019s disease. Front. Neurosci. 12, 1\u201318 (2018).","journal-title":"Front. Neurosci."},{"key":"56735_CR14","first-page":"1","volume":"1","author":"RM Meade","year":"2019","unstructured":"Meade, R. M., Fairlie, D. P. & Mason, J. M. Alpha-synuclein structure and Parkinson\u2019s disease\u2014Lessons and emerging principles. Mol. Neurodegener. 1, 1\u201314 (2019).","journal-title":"Mol. Neurodegener."},{"key":"56735_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbr.2017.11.025","volume":"339","author":"S Frahm","year":"2018","unstructured":"Frahm, S. et al. Alpha-synuclein transgenic mice, h-\u03b1-SynL62, display \u03b1-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson\u2019s disease. Behav. Brain Res. 339, 153\u2013168 (2018).","journal-title":"Behav. Brain Res."},{"key":"56735_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2017.00447","volume":"10","author":"K Schwab","year":"2018","unstructured":"Schwab, K. et al. A protein aggregation inhibitor, leuco-methylthioninium bis(hydromethanesulfonate), decreases \u03b1-synuclein inclusions in a transgenic mouse model of synucleinopathy. Front. Mol. Neurosci. 10, 1\u201315 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"56735_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110386","author":"K Schwab","year":"2022","unstructured":"Schwab, K. et al. Glutamatergic transmission and receptor expression in the synucleinopathy h-\u03b1-synL62 mouse model: Effects of hydromethylthionine. Cell. Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110386 (2022).","journal-title":"Cell. Signal."},{"key":"56735_CR18","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1021\/acschemneuro.8b00274","volume":"10","author":"M K\u00f6nig","year":"2019","unstructured":"K\u00f6nig, M. et al. Increased cholinergic response in \u03b1-synuclein transgenic mice (h-\u03b1-synL62). ACS Chem. Neurosci. 10, 1915\u20131922 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"56735_CR19","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00018-014-1804-z","volume":"72","author":"V Melis","year":"2015","unstructured":"Melis, V. et al. Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer\u2019s disease and frontotemporal lobar degeneration. Cell. Mol. Life Sci. 72, 2199\u20132222 (2015).","journal-title":"Cell. Mol. Life Sci."},{"key":"56735_CR20","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"56735_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ng0398-231","volume":"18","author":"NG Larsson","year":"1998","unstructured":"Larsson, N. G. et al. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson\u2019s disease. Nat. Genet. 18, 231\u2013236 (1998).","journal-title":"Nat. Genet."},{"key":"56735_CR22","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","volume":"20","author":"H Van Der Putten","year":"2000","unstructured":"Van Der Putten, H. et al. Neuropathology in mice expressing human \u03b1-synuclein. J. Neurosci. 20, 6021\u20136029 (2000).","journal-title":"J. Neurosci."},{"key":"56735_CR23","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah, E. et al. Dopaminergic loss and inclusion body formation in \u03b1-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265\u20131269 (2000).","journal-title":"Science"},{"key":"56735_CR24","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee, M. K. et al. Human \u03b1-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 \u2192 Thr mutation causes neurodegenerative disease with \u03b1-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99, 8968\u20138973 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"56735_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0197-4580(02)00091-X","volume":"24","author":"T Gomez-Isla","year":"2003","unstructured":"Gomez-Isla, T. et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human \u03b1-synuclein A30P transgenic mice. Neurobiol. Aging 24, 245\u2013258 (2003).","journal-title":"Neurobiol. Aging"},{"key":"56735_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/exnr.2002.7882","volume":"175","author":"EK Richfield","year":"2002","unstructured":"Richfield, E. K. et al. Behavioral and neurochemical effects of wild-type and mutated human \u03b1-synuclein in transgenic mice. Exp. Neurol. 175, 35\u201348 (2002).","journal-title":"Exp. Neurol."},{"key":"56735_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1006\/nbdi.2001.0392","volume":"8","author":"Y Matsuoka","year":"2001","unstructured":"Matsuoka, Y. et al. Lack of nigral pathology in transgenic mice expressing human \u03b1-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535\u2013539 (2001).","journal-title":"Neurobiol. Dis."},{"key":"56735_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1044-7431(03)00198-2","volume":"24","author":"S Gispert","year":"2003","unstructured":"Gispert, S. et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24, 419\u2013429 (2003).","journal-title":"Mol. Cell. Neurosci."},{"key":"56735_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson, B. I. et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521\u2013533 (2002).","journal-title":"Neuron"},{"key":"56735_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein, E. et al. Differential neuropathological alterations in transgenic mice expressing \u03b1-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568\u2013578 (2002).","journal-title":"J. Neurosci. Res."},{"key":"56735_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12565-018-0464-8","volume":"94","author":"K Taguchi","year":"2019","unstructured":"Taguchi, K., Watanabe, Y., Tsujimura, A. & Tanaka, M. Expression of \u03b1-synuclein is regulated in a neuronal cell type-dependent manner. Anat. Sci. Int. 94, 11\u201322 (2019).","journal-title":"Anat. Sci. Int."},{"key":"56735_CR32","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41380-021-01296-7","volume":"27","author":"YJ Guo","year":"2022","unstructured":"Guo, Y. J., Xiong, H., Chen, K., Zou, J. J. & Lei, P. Brain regions susceptible to alpha-synuclein spreading. Mol. Psychiatry 27, 758\u2013770 (2022).","journal-title":"Mol. Psychiatry"},{"key":"56735_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00401-022-02406-7","volume":"143","author":"L de Boni","year":"2022","unstructured":"de Boni, L. et al. Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by \u03b1-synuclein conformations. Acta Neuropathol. 143, 453\u2013469 (2022).","journal-title":"Acta Neuropathol."},{"key":"56735_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2021.01.010","volume":"101","author":"S Roshanbin","year":"2021","unstructured":"Roshanbin, S. et al. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice. Neurobiol. Aging 101, 207\u2013220 (2021).","journal-title":"Neurobiol. Aging"},{"key":"56735_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","volume":"37","author":"R Sharon","year":"2003","unstructured":"Sharon, R. et al. The formation of highly soluble oligomers of \u03b1-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease. Neuron 37, 583\u2013595 (2003).","journal-title":"Neuron"},{"key":"56735_CR36","first-page":"1","volume":"18","author":"NP du Sert","year":"2020","unstructured":"du Sert, N. P. et al. The arrive guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, 1\u201312 (2020).","journal-title":"PLoS Biol."},{"key":"56735_CR37","volume-title":"The Mouse Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"2019","unstructured":"Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates 5th edn. (Academic Press, 2019).","edition":"5"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56735-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56735-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T21:25:14Z","timestamp":1710451514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56735-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["56735"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-56735-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6239"}}